OKYO Pharma ratios data for the quarter ended Mar 2026. These financial ratios cover 10 quarters of results from Mar 2022 through Mar 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Mar2022 | Mar2023 | Sep2023 | Mar2024 | Sep2024 | Dec2024 | Mar2025 | Sep2025 | Dec2025 | Mar2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Efficiency | ||||||||||
| Assets AverageAssets Avg. | 0.01B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | ||||
| Invested CapitalInvested Cap. | 47.04B | -0.00B | -0.01B | -0.01B | -0.01B | -0.00B | -0.00B | |||
| Leverage & Solvency | ||||||||||
| Debt Ratio | 0.00B | 0.15 | 0.22 | 0.23 | 0.16 | 0.23 | 0.09 | |||
| Valuation | ||||||||||
| Price to BookP/B | -209.59 | -170.49 | -94.97 | -153.96 | -393.97 | 87.81 | ||||
| Enterprise Value | 1.24B | 1.00B | 0.69B | 0.77B | 0.85B | 1.34B | 1.39B | 1.06B | ||
| Market Capitalization | 1.24B | 1.00B | 0.69B | 0.77B | 0.85B | 1.35B | 1.39B | 1.08B | ||
| Price to FCFP/FCF | -81.52 | -0.00B | 0.18 | |||||||
| EV to FCF | -81.10 | -0.00B | 0.17 | |||||||
| EV to CFO | -81.10 | -0.00B | -179.01 |